179 related articles for article (PubMed ID: 19875761)
1. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Sweetenham JW; Goldman B; LeBlanc ML; Cook JR; Tubbs RR; Press OW; Maloney DG; Fisher RI; Rimsza LM; Braziel RM; Hsi ED
Ann Oncol; 2010 Jun; 21(6):1196-1202. PubMed ID: 19875761
[TBL] [Abstract][Full Text] [Related]
2. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
3. Biologic predictors in follicular lymphoma: importance of markers of immune response.
Kelley T; Beck R; Absi A; Jin T; Pohlman B; Hsi E
Leuk Lymphoma; 2007 Dec; 48(12):2403-11. PubMed ID: 18067016
[TBL] [Abstract][Full Text] [Related]
4. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
Farinha P; Al-Tourah A; Gill K; Klasa R; Connors JM; Gascoyne RD
Blood; 2010 Jan; 115(2):289-95. PubMed ID: 19901260
[TBL] [Abstract][Full Text] [Related]
5. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
6. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
[TBL] [Abstract][Full Text] [Related]
8. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
9. The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease.
Koch K; Hoster E; Unterhalt M; Ott G; Rosenwald A; Hansmann ML; Engelhard M; Hiddemann W; Klapper W
Hum Pathol; 2012 Dec; 43(12):2274-81. PubMed ID: 22795355
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
11. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
[TBL] [Abstract][Full Text] [Related]
13. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).
Farinha P; Masoudi H; Skinnider BF; Shumansky K; Spinelli JJ; Gill K; Klasa R; Voss N; Connors JM; Gascoyne RD
Blood; 2005 Sep; 106(6):2169-74. PubMed ID: 15933054
[TBL] [Abstract][Full Text] [Related]
14. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
Chevalier N; Mueller M; Mougiakakos D; Ihorst G; Marks R; Schmitt-Graeff A; Veelken H
Leuk Lymphoma; 2016 Sep; 57(9):2150-60. PubMed ID: 26757600
[TBL] [Abstract][Full Text] [Related]
16. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
Carreras J; Lopez-Guillermo A; Roncador G; Villamor N; Colomo L; Martinez A; Hamoudi R; Howat WJ; Montserrat E; Campo E
J Clin Oncol; 2009 Mar; 27(9):1470-6. PubMed ID: 19224853
[TBL] [Abstract][Full Text] [Related]
17. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
[TBL] [Abstract][Full Text] [Related]
18. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
McLaughlin P
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
20. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
